摘要
目的探讨尼卡地平治疗妊娠期高血压的临床疗效和安全性。方法选择2009年3月至2010年3月上海交通大学医学院附属仁济医院、首都医科大学附属北京妇产医院和浙江大学医学院附属妇产科医院收治的的妊娠期高血压患者62例,随机分为尼卡地平组32例和拉贝洛尔组30例。观察各组治疗前后的血压变化情况、围产儿结局和药物不良反应。结果尼卡地平组患者在用药1 h后达到目标血压,13例患者24 h后改为口服用药,7例患者需要联合降压治疗。拉贝洛尔组患者用药4 h达到目标血压,9例患者改为口服,11例患者联合降压治疗。两组降压疗效差异具有统计学意义(P<0.05)。尼卡地平组新生儿体重和胎盘重量明显高于拉贝洛尔组(P<0.05)。两组患者用药前后心率变化差异无统计学意义(P>0.05)。结论尼卡地平可有效控制血压,可改善围产儿结局。
Objective To evaluate the clinical efficacy and safety of nicardipine in treatment of hypertensive disorder complicating pregnancy. Methods Sixty-two women with severe hypertensive disorder complicating pregnancy registered to three hospitals between March 2009 and March 2010 were included in this study. These patients were divided into two groups randomly to receive treatment with labetalol （ n = 30） or nieardipine （ n = 32 ）. Changes of blood pressure before and after treatment, perinatal outcomes and side effects of medication were observed in both groups. Results In nicardipine group,the target levels of blood pressure were achieved at 1 hour after medication. The medication was shifted to oral use in 13 cases ,which 7 patients required treatment in combination with other antihypertensive drugs. In the labetalol group, the target levels of blood pressure were achieved at 4 hours after medication. The medication was shifted to oral use in 9 cases, which 11 patients required treatment in combination with other antihypertensive drugs. There were a significant difference in antihypertensive effects between two groups（ P 〈0. 05 ）. The birth weight and placenta weight in nicardipine group were significantly greater than those in labetalol group（ P 〈 0. 05 ）. There was no statistic difference in changes of heart rate before and after treatment in two groups （ P 〉 0. 05 ）. Conclusion Nieardipine may provide effective control of blood pressure and better pregnancy outcome for women with severe hypertensive disorder complicating pregnancy.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2011年第10期789-790,共2页
Chinese Journal of Practical Internal Medicine
关键词
尼卡地平
拉贝洛尔
降压
围产结局
安全性
nicardipine
labetalol
antihypertension
pefinatal outcomes
safety
